Who
Julianne Bruno
Director
Company insider
Files Form 4 as: Director, Damora Therapeutics; Chief Operating Officer, CRISPR Therapeutics AG.
In numbers
- Trades disclosed
- 25
- Buys
- 0
- Sells
- 5
- Bought
- $0
- Sold
- $336K
- Companies
- 2
- Companies where not an officer
- 1
- First trade
- 23 May 2024
- Last trade
- 23 Mar 2026
- Last filed
- 25 Mar 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 23 Mar 2026filed 25 Mar 2026 | DMRA Damora Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —37,313 at $0.00 | filing |
| 23 Mar 2026filed 25 Mar 2026 | DMRA Damora Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —37,313 at $0.00 | filing |
| 9 Feb 2026filed 12 Feb 2026 | GalectoBiotechnology | SEC FORM 4 Code M | —129,000 at $0.00 | filing |
| 9 Feb 2026filed 12 Feb 2026 | Galectooption or derivative · Biotechnology | SEC FORM 4 Code M | —129 at $0.00 | filing |
| 9 Feb 2026filed 12 Feb 2026 | DMRA Damora Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —129 at $0.00 | filing |
| 9 Feb 2026filed 12 Feb 2026 | DMRA Damora TherapeuticsBiotechnology | SEC FORM 4 Code M | —129,000 at $0.00 | filing |
| 21 Mar 2025filed 24 Mar 2025 | CRSP CRISPR Therapeutics AGGenomics & Gene Editing | SEC FORM 4 Sold | $71K1,714 at $41.23 | filing |
| 20 Mar 2025filed 24 Mar 2025 | CRSP CRISPR Therapeutics AGoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code M | —3,750 | filing |
| 20 Mar 2025filed 24 Mar 2025 | CRSP CRISPR Therapeutics AGGenomics & Gene Editing | SEC FORM 4 Code M | —3,750 | filing |
| 14 Mar 2025filed 18 Mar 2025 | CRSP CRISPR Therapeutics AGoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code A | —36,666 at $0.00 | filing |
| 14 Mar 2025filed 18 Mar 2025 | CRSP CRISPR Therapeutics AGoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code A | —27,500 at $0.00 | filing |
| 12 Mar 2025filed 12 Mar 2025 | CRSP CRISPR Therapeutics AGGenomics & Gene Editing | SEC FORM 4 Sold | $8,231190 at $43.32 | filing |
| 11 Mar 2025filed 12 Mar 2025 | CRSP CRISPR Therapeutics AGoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code M | —435 | filing |
| 11 Mar 2025filed 12 Mar 2025 | CRSP CRISPR Therapeutics AGGenomics & Gene Editing | SEC FORM 4 Sold | $51K1,198 at $42.42 | filing |
| 11 Mar 2025filed 12 Mar 2025 | CRSP CRISPR Therapeutics AGGenomics & Gene Editing | SEC FORM 4 Code M | —435 | filing |
| 10 Mar 2025filed 12 Mar 2025 | CRSP CRISPR Therapeutics AGoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code M | —2,399 | filing |
| 10 Mar 2025filed 12 Mar 2025 | CRSP CRISPR Therapeutics AGGenomics & Gene Editing | SEC FORM 4 Code M | —2,399 | filing |
| 19 Feb 2025filed 19 Feb 2025 | CRSP CRISPR Therapeutics AGGenomics & Gene Editing | SEC FORM 4 Sold | $18K333 at $52.80 | filing |
| 18 Feb 2025filed 19 Feb 2025 | CRSP CRISPR Therapeutics AGoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code M | —650 | filing |
| 18 Feb 2025filed 19 Feb 2025 | CRSP CRISPR Therapeutics AGGenomics & Gene Editing | SEC FORM 4 Code M | —650 | filing |
News
CRISPR Therapeutics Announces Chief Financial Officer TransitionCRSP · manilatimes.net · 19 Oct 2026Where Will CRISPR Therapeutics Stock Be in 2030?CRSP · aol.com · 18 Oct 2026Cathie Wood Bought More CRISPR Therapeutics Stock 2 Days in a Row. Here's What She Sees in the Biotech Stock.CRSP · aol.com · 18 Oct 2026
0 headlines in the last 90 days name Julianne Bruno; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.